Genetic factors and the risk of cardiovascular diseases

1. Abe M, Nakura J, Yamamoto M et al. Association of GNAS1 gene variant with hypertension depending on smoking status. Hypertension 2002; 40: 261-265.

2. Alberts B et al. Molecular Biology of the Cell. Garland Publ. 1994

3. Allayee H, Aouizerat BE, Cantor RM et al. Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype. Am J Hum Genet 1998; 63: 577-585.

4. Alvarez R, Gonzalez P, Batalla A et al. Association between the NOS3 (-786 T/C) and the ACE (I/D) DNA genotypes and early coronary artery disease. Nitric Oxide 2001; 5: 343-348.

5. Arimura T, Nakamura T, Hiroi S et al. Characterization of the human nebulette gene: a polymorphism in an actin-binding motif is associated with nonfamilial idiopathic dilated cardiomyopathy. Hum Genet 2000; 107: 440-451.

6. Assmus B, Urbich C, Aicher A et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003; 92: 1049-1055.

7. Babunova NB, Minushkina LO, Zateishchikov DA et al. Association of the T174M and M235T polymorphisms of the angiotensinogen gene with myocardial ischemia in the Russian population of the city of Moscow. Mol Biol (Mosk) 2003; 37: 57-60.

8. Baker EH, Dong YB, Sagnella GA et al. Association of hypertension with T594M mutation in beta subunit of epithelial sodium channels in black people resident in London. Lancet 1998; 351: 1388-1392.

9. Barrans JD, Allen PD, Stamatiou D et al. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular- based cDNA microarray. Am J Pathol 2002; 160: 2035-2043.

10. Barrans JD, Ip J, Lam CW et al. Chromosomal distribution of the human cardiovascular transcriptome. Genomics 2003; 81: 519-524.

11. Barrans JD, Stamatiou D, Liew C. Construction of a human cardiovascular cDNA microarray: portrait of the failing heart. Biochem Biophys Res Commun 2001; 280: 964-969.

12. Batalla A, Alvarez R, Reguero JR et al. Synergistic effect between apolipoprotein E and angiotensinogen gene polymorphisms in the risk for early myocardial infarction. Clin Chem 2000; 46: 1910-1915.

13. Bátorová A, Horváthová D, de Moerloose P et al. Fenotypová a genotypová analýza vrodenej hypofibrinogenémie a dysfibrinogenémie. Vnitř Lék 2005; 51: 802-808.

14. Benes P, Muzik J, Benedik J et al. The C766T low-density lipoprotein receptor related protein polymorphism and coronary artery disease, plasma lipoproteins, and longevity in the Czech population. J Mol Med 2001; 79: 116-120.

15. Bergman RN, Zaccaro DJ, Watanabe RM et al. Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than homeostasis model assessment or fasting insulin. Diabetes 2003; 52: 2168-2174.

16. Biggart S, Chin D, Fauchon M et al. Association of genetic polymorphismsin the ACE, ApoE, and TGF beta genes with early onset ischemic heart disease. Clin Cardiol 1998; 21: 831-836.

17. Bolla MK, Miller GJ, Yellon DM et al. Analysis of the association of a heat shock protein70-1 gene promoter polymorphism with myocardial infarction and coronary risk traits. Dis Markers 1998; 13: 227-235.

18. Brdlička R. Lidský genóm na rozhraní tisíciletí. Grada publishing 2000: 2-91.

19. Campos AH, Zhao Y, Pollman MJ et al. DNA microarray profiling to identify angiotensin-responsive genes in vascular smooth muscle cells: potential mediators of vascular disease. Circ Res 2003; 92: 111-118.

20. Crook ED. The genetics of human hypertension. Semin Nephrol 2002; 22: 27-34.

21. Dai K, Gao W, Ruan C. The Sma I polymorphism in the von Willebrand factor gene associated with acute ischemic stroke. Thromb Res 2001; 104: 389-395.

22. Dalloz F, Osinska H, Robbins J. Manipulating the contractile apparatus: genetically defined animal models of cardiovascular disease. J Mol Cell Cardiol 2001; 33: 9-25.

23. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8: 1-21.

24. De Bacquer D, De Backer G, Langlois M et al. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis 2001; 157: 161-166.

25. Dempsey AA, Dzau VJ, Liew CC. Cardiovascular genomics: estimating the total number of genes expressed in the human cardiovascular system. J Mol Cell Cardiol 2001; 33: 1879-1886.

26. DePrimo SE, Wong LM, Khatry DB et al. Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. BMC Cancer 2003; 3: 3.

27. Ferrarotti I, Zorzetto M, Beccaria M et al. Tumour necrosis factor family genes in a phenotype of COPD associated with emphysema. Eur Respir J 2003; 21: 444-449.

28. Fortunato G, Rubba P, Panico S et al. A paraoxonase gene polymorphism, PON 1 (55), as an independent risk factor for increased carotid intima-media thickness in middle-aged women. Atherosclerosis 2003; 167: 141-148.

29. Gabriel SB, Schaffner SF, Nguyen H et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.

30. Gardeman NA, Stricker J, Humme J et al. Angiotensinogen T174M and M235T gene polymorphisms are associated with the extent of coronary atherosclerosis. Atherosclerosis 1999; 145: 309-314.

31. Garenc C, Perusse L, Chagnon YC et al. The alpha 2-adrenergic receptor gene and body fat content and distribution: the HERITAGE Family Study. Mol Med 2002; 8: 88-94.

32. Gavorník P. Ateroskleróza a iné choroby tepien. Univerzita Komenského Bratislava 1999.

33. Geraci MW, Gao B, Hoshikawa Y et al. Genomic approaches to research in pulmonary hypertension. Respir Res 2001; 2: 210-215.

34. Gibbons M et al. Genetic Markers: Progress and Potential for Cardiovascular Diseases. Circulation 2004; 109: IV47-IV58.

35. Girerd X, Hanon O, Mourad JJ et al. Lack of association between renin-angiotensin system, gene polymorphisms, and wall thickness of the radial and carotid arteries. Hypertension 1998; 32: 579-583.

36. Ghilardi G, Biondi ML, DeMonti M et al. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke 2002; 33: 2408-2412.

37. Goldstein JL, Brown MS. The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy. Med Clin North Am 1982; 66: 335-362.

38. Gonzalez P, Alvarez R, Batalla A et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun 2001; 2: 191-195.

39. Goodarzi MO, Guo X, Taylor KD et al. Lipoprotein lipase is a gene for insulin resistance in Mexican-Americans. Diabetes 2004; 53: 214-220.

40. Goodarzi MO, Guo X, Taylor KD et al. Determination and use of haplotypes: ethnic comparison and association of the lipoprotein lipase gene and coronary artery disease in Mexican-Americans. Genet Med 2003; 5: 322-327.

41. Gretarsdottir S, Thorleifsson G, Reynisdottir ST et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 2003; 35: 131-138.

42. Gumulec J, Penka M, Richterová R et al. Glykoprotein IIb/IIIa destičkové membrány z hlediska jeho genetických změn. Vnitř Lék 2005; 51: 845-853.

43. Gumulec J, Penka M, Richterová R et al. Glykoprotein Ia/IIa destičkové membrány z hlediska jeho genetických změn. Vnitř Lék 2005; 51: 840-844.

44. Gumulec J, Penka M, Richterová R et al. Glykoproteiny destičkové membrány z hlediska jeho genetických změn. Vnitř Lék 2005; 51: 833-839.

45. Haddy N, Sass C, Droesch S et al. IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 2003; 170: 277-283.

46. Havndrup O, Bundgaard H, Andersen PS et al. A novel missense mutation, Leu390Val, in the cardiac beta-myosin heavy chain associated with pronounced septal hypertrophy in two families with hypertrophic cardiomyopathy. Scand Cardiovasc J 2000; 34: 558-563.

47. Herd JA, Ballantyne CM, Stein EA et al. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 2000; 36: 1572-1578.

48. Herrington DM, Howard TD, Brosnihan KB et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002; 105: 1879-1882.

49. Herrington DM, Howard TD, Hawkins GA et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002; 346: 967-974.

50. Hessner MJ, Dinauer DM, Kwiatkowski R et al. Age-dependent prevalence of vascular disease-associated polymorphisms among 2689 volunteer blood donors. Clin Chem 2001; 47: 1879-1884.

51. Higashi K, Ishikawa T, Ito T et al. Association of a genetic variation in the beta 3- adrenergic receptor gene with coronary heart disease among Japanese. Biochem Biophys Res Commun 1997; 232: 728-730.

52. Hoffee PA. Medical Molecular Genetics. Fence Creek Publ 1998.

53. Holmer SR, Hengstenberg C, Mayer B et al. Lipoprotein lipase gene polymorphism, cholesterol subfractions and myocardial infarction in large samples of the general population. Cardiovasc Res 2000; 47: 806-812.

54. Holweg CT, Baan CC, Niesters HG et al. TGF-beta1 gene polymorphisms in patients with end-stage heart failure. J Heart Lung Transplant 2001; 20: 979-984.

55. Hopkins PN et al. Blunteed renal vascular response to angiotesin II is associated with the common variant of the angiotensinogene gene and obesity. Journal of Hypertension 1996; 14: 199-207.

56. Hou L, Osei-Hyiaman D, Yu H et al. Association of a 27-bp repeat polymorphism in ecNOS gene with ischemic stroke in Chinese patients. Neurology 2001; 56: 490-496.

57. Hudeček J, Dobrotová M, Hybenová J et al. Faktor V Leiden a slovenská populace. Vnitř Lék 2003; 49: 845-850.

58. Hulín I et al. Patofyziológia. 5. ed. Bratislava: Slovak Acadamic Press 2002.

59. Hunter DJ. Gene-environment interactions in human diseases. Nature reviews genetics 2005; 6: 287-298.

60. Hwang JJ, Allen PD, Tseng GC et al. Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genomics 2002; 10: 31-44.

61. Hwang DM, Dempsey AA, Wang RX et al. A genome-based resource for molecular cardiovascular medicine: toward a compendium of cardiovascular genes. Circulation 1997; 96: 4146-4203.

62. Chapman CM, Palmer LJ, McQuillan BM et al. Polymorphisms in the angiotensinogen gene are associated with carotid intimal-medial thickening in females from a community-based population. Atherosclerosis 2001; 159: 209-217.

63. Chen Q, Reis SE, Kammerer CM et al. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored.

64. Cheng LS, Davis RC, Raffel LJ et al. Coincident linkage of fasting plasma insulin and blood pressure to chromosome 7q in hypertensive Hispanic families. Circulation 2001; 104: 1255-1260.

65. Chiang FT, Chiu KC, Tseng YZ et al. Nucleotide(-258) G-to-A transition variant of the liver glucokinase gene is associated with essential hypertension. Am J Hypertens 1997; 10: 1049-1052.

66. Cho Y, Somer BG, Amatya A. Natriuretic peptides and their therapeutic potential. Heart Dis 1999; 1: 305-328.

67. Illingworth DR Lipid-lowering drugs. An overview of indications and optimum therapeutic use. Drugs 1987; 33: 259-279.

68. Ireland H, Kunz G, Kyriakoulis K et al. Thrombomodulin gene mutations associated with myocardial infarction. Circulation 1997; 96: 15-18.

69. Jáchymová M, Horký K, Jindra A et al. Esencialni hypertenze a Arg16Gly polymorfizmus genu pro Beta2-adrenergni receptor. Vnitř Lék 2005; 51: 945-949.

70. Jia H, Hingorani AD, Sharma P et al. Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 1999; 34: 8-14.

71. Kanters JK, Larsen LA, Orholm M et al. Novel donor splice site mutation in the KVLQT1 gene is associated with long QT syndrome. J Cardiovasc Electrophysiol 1998; 9: 620-624.

72. King RA, Rotter JI, Motulsky AG (eds.) The Genetic Basis of Common Diseases. 2nd ed. New York: Oxford University Press 2002.

73. Kohlmann A, Schoch C, Schnittger S et al. Molecular characterization of acute leukemias by use of microarray technology. Genes Chromosomes Cancer 2003; 37: 396-405.

74. Kosachunhanun N, Hunt SC, Hopkins PN et al. Genetic determinants of nonmodulating hypertension. Hypertension 2003; 42: 901-908.

75. Koschinsky ML, Boffa MB, Nesheim ME et al. Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activatable fibrinolysis inhibitor (TAF1) with blood pressure. Clin Genet 2001; 60: 345-349.

76. Kubaszek A, Pihlajamaki J, Karhapaa P et al. The K121Q polymorphism of the PC-1 gene is associated with insulin resistance but not with dyslipidemia. Diabetes Care 2003; 26: 464-467.

77. Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338: 86-93.

78. Kuroki S, Ikeda U, Maeda Y et al. Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and vasospastic angina. Clin Cardiol 1997; 20: 873-876.

79. Lacquemant C, Lepretre F, Pineda Torra I et al. Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab 2000; 26: 393-401.

80. Lewin B. Genes VII. Oxford Univ Press 2000.

81. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104: 545-556.

82. Liew CC. Heart failure: a genomics approach. In: Van Eyk JE, Dunn MJ (eds.) Proteomic and Genomic Analysis of Cardiovascular Disease. Weinheim: Wiley-VCH Verlag GmbH & Co 2003: 4-60.

83. Lin RC, Wang XL, Morris BJ. Association of coronary artery disease with glucocorticoid receptor N363S variant. Hypertension 2003; 41: 404-407.

84. Lithfield WR et al. Increased urinary free cortisol: a potential intermediate fenotype for essential hypertension. Am J Hum Genet 1998; 31: 569-574.

85. Lombardi R, Betocchi S. Aetiology and pathogenesis of hypertrophic cardiomyopathy. Acta Paediatr Suppl 2002; 91: 10-14.

86. Lovati E, Richard A, Frey BM et al. Genetic polymorphisms of the renin-angiotensin- aldosterone system in end-stage renal disease. Kidney Int 2001; 60: 46-54.

87. Lu K, Lee MH, Hazard S et al. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet 2001; 69: 278-290.

88. Luft FC. Twins in cardiovascular genetic research. Hypertension 2001; 37(2 Part 2): 350-356.

89. Lusis G et al. Genetic Basis of Atherosclerosis. Circulation 2004; 110: 1868-1873.

90. Ma J, Liew CC. Gene profiling identifies secreted protein transcripts from peripheral blood cells in coronary artery disease. J Mol Cell Cardiol 2003; 35: 993-998.

91. Mackness B, Hunt R, Durrington PN et al. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 1233-1238.

92. Marian AJ, Safavi F, Ferlic L et al. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the Lipoprotein and Coronary Atherosclerosis Study. J Am Coll Cardiol 2000; 35: 89-95.

93. Margaglione M, Cappucci G, Colaizzo D et al. C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives. Arterioscler Thromb Vasc Biol 2000; 20: 198-203.

94. Mayani H, Alvarado-Moreno JA, Flores-Guzman P. Biology of human hematopoietic stem and progenitor cells present in circulation. Arch Med Res 2003; 34: 476-488.

95. Mazurek T, Zhang L, Zalewski A et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003; 108: 2460-2466.

96. Mialet Perez J, Rathz DA, Petrashevskaya NN et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003; 9: 1300-1305.

97. Morange PE, Juhan-Vague I, Scarabin PY et al. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME Study (Prospective Epidemiological Study of MI). Thromb Haemost 2003; 89: 554-560.

98. Mori Y, Kim-Motoyama H, Ito Y et al. The Gln27Glu beta2-adrenergic receptor variant is associated with obesity due to subcutaneous fat accumulation in Japanese men. Biochem Biophys Res Commun 1999; 258: 138-140.

99. Morrison AC, Bray MS, Folsom AR et al. ADD1 460W allele associated with cardiovascular disease in hypertensive individuals. Hypertension 2002; 39: 1053-1057.

100. Murray A, Donger C, Fenske C et al. Splicing mutations in KCNQ1: a mutation hot spot at codon 344 that produces in frame transcripts. Circulation 1999; 100: 1077-1084.

101. Nassar BA, Bevin LD, Johnstone DE et al. Relationship of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and early-onset coronary artery disease. Am Heart J 2001; 142: 586-589.

102. Niimura H, Patton KK, McKenna WJ et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 2002; 105: 446-451.

103. Nikitin AG, Gorashko NM, Minushkina LO et al. Association of the G7831A polymorphism of the ACE gene with myocardial ischemia in the Moscow population. Mol Biol (Mosk) 2003; 37: 54-56.

104. Nishiuma S, Kario K, Yakushijin K et al. Genetic variation in the promoter region of the beta-fibrinogen gene is associated with ischemic stroke in a Japanese population. Blood Coagul Fibrinolysis 1998; 9: 373-379.

105. Ogawa S, Emi M, Shiraki M et al. Association of estrogen receptor beta (ESR2) gene polymorphism with blood pressure. J Hum Genet 2000; 45: 327-330.

106. Ohtoshi K, Yamasaki Y, Gorogawa S et al. Association of (-)786T-C mutation of endothelial nitric oxide synthase gene with insulin resistance. Diabetologia 2002; 45: 1594-1601.

107. Okada H, Murakami S. Cytokine expression in periodontal health and disease. Crit Rev Oral Biol Med 1998; 9: 248-266.

108. Ortlepp JR, Hoffmann R, Ohme F et al. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 2001; 85: 635-638.

109. Ozaki K, Ohnishi Y, Iida A et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32: 650-654.

110. Packard CJ, O’Reilly DS, Caslake MJ et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343: 1148-1155.

111. Patel R, Lim DS, Reddy D et al. Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol 2000; 32: 2369-2377.

112. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001; 158: 183-193.

113. Pereira AC, Cuoco MA, Mota GF et al. Hemochromatosis gene variants in patients with cardiomyopathy. Am J Cardiol 2001; 88: 388-391.

114. Pritchard PH, Frohlich J. Apoprotein A-I and lecithin: cholesterol acyltransferase in a patient with Tangier disease. Adv Exp Med Biol 1986; 201: 105-110.

115. Province MA, Kardia SL, Ranade K et al. A meta-analysis of genome-wide linkage scans for hypertension: the National Heart, Lung and Blood Institute Family Blood Pressure Program. Am J Hypertens 2003; 16: 144-147.

116. Rasmussen ML, Folsom AR, Catellier DJ et al. A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2001; 154: 739-746.

117. Reis MM, Higuchi Mde L, Benvenuti LA et al. An in situ quantitative immunohistochemical study of cytokines and IL-2Rin chronic human chagasic myocarditis: correlation with the presence of myocardial Trypanosoma cruzi antigens. Clin Immunol Immunopathol 1997; 83: 165-172.

118. Risley P, Jerrard-Dunne P, Sitzer M et al. Promoter polymorphism in the endotoxin receptor (CD14) is associated with increased carotid atherosclerosis only in smokers: the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2003; 34: 600-604.

119. Rodriguez-Perez JC, Rodriguez-Esparragon F, Hernandez-Perera O et al. Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: the PROCAGENE study. Prospective Cardiac Gene. J Am Coll Cardiol 2001; 37: 1536-1542.

120. Rook MB, Bezzina Alshinawi C, Groenewegen WA et al. Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc Res 1999; 44: 507-517.

121. Rossi GP, Taddei S, Virdis A et al. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol 2003; 41: 938-945.

122. Rosypal S. Úvod do molekulární biologie. Zväzky 1/2 a dodatok. Brno 1996, 1997.

123. Rotter JI, Bu X, Cantor RM et al. Multilocus genetic determinants of LDL particle size in coronary artery disease families. Am J Hum Genet 1996; 58: 585-594.

124. Rutherford S, Johnson MP, Curtain RP et al. Chromosome 17 and the inducible nitric oxide synthase gene in human essential hypertension. Hum Genet 2001; 109: 408-415.

125. Ryan AS, Nicklas BJ, Berman DM et al. The insertion/deletion polymorphism of the ACE gene is related to insulin sensitivity in overweight women. Diabetes Care 2001; 24: 1646-1652.

126. Sasaoka T, Kimura A, Hohta SA et al. Polymorphisms in the plateletendothelial cell adhesion molecule-1 (PECAM-1) gene, Asn563Ser and Gly670Arg, associated with myocardial infarction in the Japanese. Ann N Y Acad Sci 2001; 947: 259-269.

127. Sebastiani P, Lazarus R, Weiss ST et al. Minimal haplotype tagging. Proc Natl Acad Sci U.S.A. 2003; 100: 9900-9905.

128. Seidman CE, Seidman JG Hypertrophic cardiomyopathy. In: Scriver CR, Beaudet AL, Sly WS et al (eds.). The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill 2001: 5433-5450.

129. Sharma P, Hingorani A, Jia H et al. Positive association of tyrosine hydroxylase microsatellite marker to essential hypertension. Hypertension 1998; 32: 676-682.

130. Sharma P, Hingorani A, Jia H et al. Quantitative association between a newly identified molecular variant in the endothelin-2 gene and human essential hypertension. J Hypertens 1999; 17: 1281-1287.

131. Schillinger M, Exner M, Mlekusch W et al. Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm. Thromb Res 2002; 106: 131-136.

132. Schunkert H. Molecular genetics of congestive heart failure. Scand Cardiovasc J Suppl 1998; 47: 37-43.

133. Schwartz GL, Turner ST, Chapman AB et al. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002; 62: 1718-1723.

134. Small KM, Wagoner LE, Levin AM et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347: 1135-1142.

135. Spence JD, Malinow MR, Barnett PA et al. Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area. Stroke 1999; 30: 969-973.

136. Sršeň Š, Sršňová K. Základy klinickej genetiky a jej molekulárna podstata. Martin: Osveta 2000.

137. Stankovic A, Zivkovic M, Glisic S et al. Angiotensin II type 1 receptor gene polymorphism and essential hypertension in Serbian population. Clin Chim Acta 2003; 327: 181-185.

138. Stavljenic-Rukavina A. Genetics of cardiovascular disease. J Internat Fed Clin Chem Available at http://www.ifcc.org/ejifcc/vol14no2/ 140206200305n.htm.

139. Stavroulakis GA, Makris TK, Krespi PG et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000; 14: 427-432.

140. Stepanov VA, Puzyrev VP, Karpov RS et al. Genetic markers in coronary artery disease in a Russian population. Hum Biol 1998; 70: 47-57.

141. Stevens PA, Brown MJ. Genetic variability of the ET-1 and the ETA receptor genes in essential hypertension. J Cardiovasc Pharmacol 1995; 26: S9-S12.

142. Strauss E, Waliszewski K, Gabriel M et al. Increased risk of the abdominal aortic aneurysm in carriers of the MTHFR 677T allele. J Appl Genet 2003; 44: 85-93.

143. Šašinka M, Šagát T et al. Pediatria. Košice: Satus 1998: 154-192.

144. Šmarda J. Člověk v proudu dědičnosti, geny v lidském zdraví a nemoci. Praha: Grada Publishing 1999.

145. Špinarová L, Toman J, Hude P et al. Poruchy lamínů pri postižení srdce a kosterního svalstva. Vnitř Lék 2003; 49: 637-641.

146. Tan KT, Dempsey A, Liew CC. Cardiac genes and gene databases for cardiovascular disease genetics. Curr Hypertens Rep 1999; 1: 51-58.

147. Tan MS, Chang SY, Chang DM et al. Association of resistin gene 3-untranslated region 62G-A polymorphism with type 2 diabetes and hypertension in a Chinese population. J Clin Endocrinol Metab 2003; 88: 1258-1263.

148. Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet 2002; 3: 391-397.

149. Tang DC, Prauner R, Liu W et al. Polymorphisms within the angiotensinogen gene (GT- repeat) and the risk of stroke in pediatric patients with sickle cell disease: a case-control study. Am J Hematol 2001; 68: 164-169.

150. Terashima M, Akita H, Kanazawa K et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999; 99: 2717-2719.

151. Tiago AD, Badenhorst D, Skudicky D et al. An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovasc Res 2002; 54: 584-589.

152. Topol EJ, McCarthy J, Gabriel S et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001; 104: 2641-2644.

153. Ton C, Stamatiou D, Dzau VJ et al. Construction of a zebrafish cDNA microarray: gene expression profiling of the zebrafish during development. Biochem Biophys Res Commun 2002; 296: 1134-1142.

154. Ton C, Stamatiou D, Liew CC. Gene expression profile of zebrafish exposed to hypoxia during development. Physiol Genomics 2003; 13: 97-106.

155. Towbin JA, Bowles NE. The failing heart. Nature 2002; 415: 227-233.

156. Tregouet DA, Barbaux S, Escolano S et al. Specific haplotypes of the P-selectin gene are associated with myocardial infarction. Hum Mol Genet 2002; 11: 2015-2023.

157. Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU et al. Variation of apolipoprotein B gene is associated with myocardial infarction and lipoprotein levels in Danes. Atherosclerosis 1991; 89: 69-81.

158. Tybjaerg-Hansen A. Rare and common mutations in hyperlipidemia and atherosclerosis, with special reference to familial defective apolipoprotein B-100. Scand J Clin Lab Invest Suppl 1995; 220: 57-76.

159. Unkelbach K, Gardemann A, Kostrzewa M et al. A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol 1999; 19: 932-938.

160. Uzui H, Harpf A, Liu M et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 2002; 106: 3024-3030.

161. Vaisanen SB, Rauramaa R, Luong LA et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2657-2662.

162. Vickers MA, Green FR, Terry C et al. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002; 53: 1029-1034.

163. Voet D, Voet JG. Straightening out the straighteners. Trends Biochem Sci 1993 18(12): 464.

164. Vohnout B, Raslova K, Gasparovic J et al. Lipid levels and their genetic regulation in patients with familial hypercholesterolemia and familial defective apolipoprotein B-100: the MEDPED Slovakia Project. Atheroscler Suppl 2003; 4: 3-5.

165. Voločik G, Rosochová I, Kovács L. Vplyv polymorfizmu ACE génu na funkciu ľavej komory u chorých s diabetom 2. typu. Vnitř Lék 2003; 49: 181-184.

166. von Beckerath N, Schusterschitz Y, Koch W et al. G protein beta 3 subunit 825T allele carriage and risk of coronary artery disease. Atherosclerosis 2003; 167: 135-139.

167. Wang Q, Shen J, Splawski I et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80: 805-811.

168. Wang XL, Greco M, Sim AS et al. Effect of CYP1A1 MspI polymorphism on cigarette smoking related coronary artery disease and diabetes. Atherosclerosis 2002; 162: 391-397.

169. Wascher TC, Paulweber B, Malaimare L et al. Associations of a human G protein beta3 subunit dimorphism with insulin resistance and carotid atherosclerosis. Stroke 2003; 34: 605-609.

170. Wauters M, Mertens I, Chagnon M et al. Polymorphisms in the leptin receptor gene, body composition and fat distribution in overweight and obese women. Int J Obes Relat Metab Disord 2001; 25: 714-720.

171. Whitney AR, Diehn M, Popper SJ et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U.S.A. 2003; 100: 1896-1901.

172. Xiang AH, Azen SP, Raffel LJ et al. Evidence for joint genetic control of insulin sensitivity and systolic blood pressure in Hispanic families with a hypertensive proband. Circulation 2001; 103: 78-83.

173. Yamada Y, Ichihara S, Izawa H et al. Association of a G994-T (Val279-Phe) polymorphism of the plasma platelet-activating factor acetylhydrolase gene with myocardial damage in Japanese patients with nonfamilial hypertrophic cardiomyopathy. J Hum Genet 2001; 46: 436-441.

174. Yamada Y, Izawa H, Ichihara S et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347: 1916-1923.

175. Yoon S, Kuivaniemi H, Gatalica Z et al. MMP13 promoter polymorphism is associated with atherosclerosis in the abdominal aorta of young black males. Matrix Biol 2002; 21: 487-498.

176. Zhang W, Needham DL, Coffin M et al. Microarray analyses of the metabolic responses of Saccharomyces cerevisiae to organic solvent dimethyl sulfoxide. J Ind Microbiol Biotechnol 2003; 30: 57-69.

177. Zhu H, Sagnella GA, Dong Y et al. Contrasting associations between aldosterone synthase gene polymorphisms and essential hypertension in blacks and in whites. J Hypertens 2003; 21: 87-95.

178. Zito F, Di Castelnuovo A, Amore C et al. Bcl I polymorphism in the fibrinogen beta-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of GISSI-2 patients. Arterioscler Thromb Vasc Biol 1997; 17: 3489-3494

179. http://www.ncbi.nlm.nih.gov/SNP/